Vinogradov Serguei V, Batrakova Elena V, Kabanov Alexander V
College of Pharmacy, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, USA.
Bioconjug Chem. 2004 Jan-Feb;15(1):50-60. doi: 10.1021/bc034164r.
Systemic delivery of oligonucleotides (ODN) to the central nervous system is needed for development of therapeutic and diagnostic modalities for treatment of neurodegenerative disorders. Macromolecules injected in blood are poorly transported across the blood-brain barrier (BBB) and rapidly cleared from circulation. In this work we propose a novel system for ODN delivery to the brain based on nanoscale network of cross-linked poly(ethylene glycol) and polyethylenimine ("nanogel"). The methods of synthesis of nanogel and its modification with specific targeting molecules are described. Nanogels can bind and encapsulate spontaneously negatively charged ODN, resulting in formation of stable aqueous dispersion of polyelectrolyte complex with particle sizes less than 100 nm. Using polarized monolayers of bovine brain microvessel endothelial cells as an in vitro model this study demonstrates that ODN incorporated in nanogel formulations can be effectively transported across the BBB. The transport efficacy is further increased when the surface of the nanogel is modified with transferrin or insulin. Importantly the ODN is transported across the brain microvessel cells through the transcellular pathway; after transport, ODN remains mostly incorporated in the nanogel and ODN displays little degradation compared to the free ODN. Using mouse model for biodistribution studies in vivo, this work demonstrated that as a result of incorporation into nanogel 1 h after intravenous injection the accumulation of a phosphorothioate ODN in the brain increases by over 15 fold while in liver and spleen decreases by 2-fold compared to the free ODN. Overall, this study suggests that nanogel is a promising system for delivery of ODN to the brain.
为了开发用于治疗神经退行性疾病的治疗和诊断方法,需要将寡核苷酸(ODN)全身性递送至中枢神经系统。注入血液中的大分子很难穿过血脑屏障(BBB),并迅速从循环中清除。在这项工作中,我们提出了一种基于交联聚乙二醇和聚乙烯亚胺的纳米级网络(“纳米凝胶”)将ODN递送至大脑的新型系统。描述了纳米凝胶的合成方法及其用特定靶向分子的修饰。纳米凝胶可以自发结合并包裹带负电荷的ODN,从而形成粒径小于100nm的聚电解质复合物的稳定水分散体。本研究使用牛脑微血管内皮细胞的极化单层作为体外模型,证明了掺入纳米凝胶制剂中的ODN可以有效地穿过血脑屏障。当纳米凝胶表面用转铁蛋白或胰岛素修饰时,转运效率进一步提高。重要的是,ODN通过跨细胞途径穿过脑微血管细胞;转运后,ODN大部分仍掺入纳米凝胶中,与游离ODN相比,ODN几乎没有降解。使用小鼠模型进行体内生物分布研究,这项工作表明,静脉注射后1小时内,由于掺入纳米凝胶中,与游离ODN相比硫代磷酸酯ODN在脑中的积累增加了15倍以上,而在肝脏和脾脏中的积累减少了2倍。总体而言,这项研究表明纳米凝胶是一种有前途的将ODN递送至大脑的系统。